预靶向在核医学临床应用中的研究进展  

Research progress in pretargeting for clinical applications in nuclear medicine

作　　者：卢海丽 高洁 李建国[2] Lu Haili;Gao Jie;Li Jianguo(Major in Medical Aspects of Specific Environments,Shanxi Medical University,Taiyuan 030012,China;Division of Radiation Medicine and Environmental Medicine,China Institute for Radiation Protection,Taiyuan 030006,China)

机构地区：[1]山西医科大学特种医学专业,太原030012 [2]中国辐射防护研究院,放射医学与环境医学研究所,太原030006

出　　处：《国际放射医学核医学杂志》2024年第5期318-322,共5页International Journal of Radiation Medicine and Nuclear Medicine

基　　金：中国辐射防护研究院创新团队基金(YC21000205)。

摘　　要：预靶向是利用特定的亲和偶联系统, 使通过两步法依次向体内注射的特异性抗体和放射性核素发生自连接, 从而达到疾病显像和(或)治疗的目的的方法。预靶向核医学显像和治疗是基于抗体的传统放射免疫疗法的替代方法, 与传统放射免疫疗法相比具有许多优势。笔者将重点对目前已进入临床研究阶段的2种预靶向策略进行讨论, 阐述其目前在疾病显像和治疗方面的研究进展, 并比较不同方法之间的优缺点。Pretargeting is a method that utilizes a specific affinity coupling system to selfattach specific antibodies and radionuclides that are sequentially injected into the body through a twostep process for disease imaging and/or treatment.Pretargeted nuclear medicine imaging and treatment is an alternative method to antibody-based conventional radioimmunotherapy,and has many advantages over conventional radioimmunotherapy.In this review,the authors will discuss two pretargeting strategies that have entered the clinical research stage,describe their current research progress in disease imaging and treatment,and compare the advantages and disadvantages of different approaches.

关 键 词：放射免疫治疗 放射性同位素 放射性核素治疗 正电子发射断层显像术 预靶向 

分 类 号：R817.5[医药卫生—影像医学与核医学]